KOSDAQBiotech & Pharma086060

GeneBioTechCo

₩4,955▼ 1.69%2026-11-18 close
Market Cap
₩42.7B
Turnover
₩84,875,720
Volume
20K
Shares out.
8.6M
PER
11.0×
PBR
0.8×
EPS
₩459
Dividend Yield
0.99%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Three Years of Rising Net Income, but Quarterly Profit Swings

GeneBioTech grew revenue to KRW 90.8 billion and attributable net income to KRW 3.79 billion in 2025, yet operating profit fell 43.4% year on year to KRW 770 million in Q3 2026, so quarterly results are moving in different directions.

  1. 1

    On a disclosed basis, revenue has risen for two consecutive years since the 2023 low, reaching KRW 90.8 billion in 2025, up 9.4% from the prior year.

  2. 2

    Attributable net income has risen for three consecutive years from 2023 through 2025, reaching KRW 3.79 billion in 2025 (up 32.2%). The company attributes the 2025 increase mainly to lower financial costs from exchange rate movements.

  3. 3

    The operating margin has eased from 5.0% in 2023 to 4.6% in 2024 and 4.3% in 2025. Operating profit in 2025 rose only 2.0% to KRW 3.92 billion.

  4. 4

    Operating profit rose 96.3% quarter on quarter to KRW 1.5 billion in Q2 2026, then fell to KRW 770 million in Q3. Q3 2026 revenue of KRW 20.6 billion was down 15.0% year on year.

  5. 5

    The debt ratio stood at 37.5% at the end of 2025, with total liabilities of KRW 20.6 billion and total equity of KRW 55 billion. Operating cash flow turned from negative in 2024 to KRW 7.61 billion in 2025.

02

Business structure

GeneBioTech makes and sells feed additives, animal health products and functional foods using biotechnology. The company presents its proprietary solid-state fermentation process as its core strength, saying it shortens production time and raises yield.

It also says that skipping purification and separation steps in enzyme production lowers manufacturing costs. Its product lineup covers feed, health supplements, functional foods, specialty processed plant protein sources, solid-state fermented probiotics, functional metabolic improvers and animal-derived protein.

Livestock farms are the main point of use for its feed-related products, where productivity and environmental compliance are the key applications. The company listed on KOSDAQ in April 2006. In September 2025 it registered a patent for a seaweed-based feed additive aimed at reducing rumen greenhouse gas emissions.

In June 2025 it completed a logistics warehouse in the Nam-Gongju Industrial Complex in Gongju, with part of the building offering temperature and humidity control for animal drug storage. The company says it continues to invest in its companion animal business and cultured meat research.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.3B₩1.4B5.6%
2025Q4₩20.5B₩900M4.5%
2026Q1₩21.5B₩800M3.6%
2026Q2₩23B₩1.5B6.5%
2026Q3₩20.6B₩800M3.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩82.8B₩1.7B₩1.5B2.0%3.3%40.1%
2023₩79.5B₩4B₩2.6B5.0%5.4%36.7%
2024₩83B₩3.8B₩2.9B4.6%5.6%41.2%
2025₩90.8B₩3.9B₩3.8B4.3%6.9%37.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a disclosed basis, annual revenue moved from KRW 82.8 billion in 2022 to KRW 79.5 billion in 2023 (down 4.0%), KRW 83 billion in 2024 (up 4.4%) and KRW 90.8 billion in 2025 (up 9.4%). After the 2023 low, revenue rose for two consecutive years, and 2025 is the largest year of the 2022 to 2025 period.

Operating profit jumped from KRW 1.67 billion in 2022 to KRW 3.95 billion in 2023 (up 136.6%), then held near KRW 4 billion, at KRW 3.84 billion in 2024 (down 2.8%) and KRW 3.92 billion in 2025 (up 2.0%).

The operating margin went from 2.0% in 2022 to 5.0% in 2023, 4.6% in 2024 and 4.3% in 2025, so margins have eased since 2023 even as sales grew. Attributable net income rose from KRW 1.52 billion in 2022 to KRW 2.59 billion in 2023 (up 70.1%), KRW 2.87 billion in 2024 (up 10.6%) and KRW 3.79 billion in 2025 (up 32.2%).

In 2025 operating profit grew only 2.0% while attributable net income grew 32.2%, and the company attributes the gap mainly to lower financial costs, including foreign exchange losses and translation losses, as the exchange rate moved.

Operating cash flow was negative KRW 3.68 billion in 2022, KRW 7.37 billion in 2023, negative KRW 464 million in 2024 and KRW 7.61 billion in 2025, changing sign almost every other year.

Quarterly, Q3 2025 revenue of KRW 24.3 billion and operating profit of KRW 1.36 billion were followed by Q4 2025 revenue of KRW 20.5 billion (down 15.3% quarter on quarter) and operating profit of KRW 916 million (down 32.6%).

Q1 2026 revenue of KRW 21.5 billion (up 4.7%) came with operating profit of KRW 763 million (down 16.7%). Q2 2026 revenue of KRW 23 billion (up 7.1%) and operating profit of KRW 1.5 billion (up 96.3%) marked a rebound.

Q3 2026 revenue of KRW 20.6 billion was down 10.4% quarter on quarter and 15.0% year on year, and operating profit of KRW 770 million was down 48.6% quarter on quarter and 43.4% year on year. Attributable net income over the last four quarters totaled KRW 3.96 billion.

05

Industry analysis

The domestic feed additive and animal health market is shaped by livestock productivity, animal disease control and environmental regulation together.

South Korea banned antibiotic growth promoters in animal feed in 2011, which increased demand for alternative additives such as fermentation-derived probiotics and enzymes. That shift lines up with GeneBioTech's focus on feed functional additives built on fermentation technology.

Greenhouse gas reduction in livestock farming is also emerging as a new demand axis. The seaweed-based rumen emission-reduction feed additive patent the company registered in September 2025 connects to this direction.

Livestock market conditions move with herd sizes and feed raw material prices, so the company's sales are also exposed to those swings. How livestock price cycles affect feed demand varies from year to year, and it is difficult to pin down where the cycle stands using numbers.

Under the biotech and pharmaceutical sector label on KOSDAQ, GeneBioTech's revenue structure is closer to a production business in the livestock value chain than to a drug developer. On the competitive side, fermentation cost competitiveness, product registration and distribution networks are the main variables.

06

Outlook

The next scheduled check point for GeneBioTech's disclosed results is its 2026 annual business report. Operating profit rebounded to KRW 1.5 billion in Q2 2026 and then fell to KRW 770 million in Q3, so whether Q4 narrows that quarterly swing is the first thing to watch.

The Nam-Gongju logistics warehouse completed in June 2025 is described as having animal drug storage capacity, which relates to how the company manages its product supply.

Whether the seaweed-based emission-reduction feed additive patent registered in September 2025 moves into commercial products and revenue is a medium-term item to track.

The company says it continues to invest in its companion animal business and cultured meat research, and the timing and scale of any revenue contribution can be gauged from the business descriptions in future periodic reports.

On ownership, filings reported that the stake held by Kim Sung-ho and a related party rose from 13.99% as of March 16, 2026 to 16.14% as of April 7, 2026. A filing also reported that Dental OK newly held a 5.01% stake as of October 27, 2026 for simple investment purposes.

The next annual report will show 2026 full-year figures to compare with the 2025 operating margin of 4.3% and operating cash flow of KRW 7.61 billion.

07

Valuation

PER
11.0×
PBR
0.8×
ROE
7.1%
EPS
₩459
BPS
₩6,678
Dividend per share
₩50

The share price trades at a level below book net asset value, with the price-to-book ratio under 1x, which means the market value sits below the KRW 55 billion of total equity on the disclosed balance sheet.

At the end of 2025 all of total equity belonged to controlling shareholders, so no adjustment for non-controlling interests is needed when reading the capital base.

Measured against attributable net income of KRW 3.96 billion over the last four quarters, the price-to-earnings relationship moves with the direction of quarterly profit. Quarterly profit moved sharply between Q2 and Q3 2026, so a single quarter alone is a weak basis for reading the multiple.

Since 2023 operating profit has stayed around KRW 4 billion, and the earnings multiple should be read alongside that gradual trend in profit. Because the multiple changes with both the share price and earnings, it helps to check the earnings trend and the price level separately.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Three Straight Years of Higher Attributable Net Income

Attributable net income rose to KRW 2.59 billion in 2023, KRW 2.87 billion in 2024 and KRW 3.79 billion in 2025, a third straight year of growth. The 32.2% increase in 2025 was the largest of the three years. Earnings have recovered from KRW 1.52 billion in 2022 to KRW 3.79 billion in 2025.

Q2 2026 Quarterly Profit Rebound

Operating profit in Q2 2026 rose 96.3% quarter on quarter to KRW 1.5 billion, and revenue grew 7.1% to KRW 23 billion. Attributable net income in the same quarter rose 128.6% to KRW 1.29 billion. Q3 attributable net income held at KRW 1.27 billion, which points to room for improvement in operating indicators.

Balance Sheet and Cash Flow Recovery

At the end of 2025, total liabilities were KRW 20.6 billion and total equity was KRW 55 billion, with a debt ratio of 37.5%. Operating cash flow turned from negative KRW 464 million in 2024 to KRW 7.61 billion in 2025. The 2025 operating cash flow was larger than the attributable net income of KRW 3.79 billion for that year.

09

Bear factors

Profit Decline in Q3 2026

Q3 2026 revenue of KRW 20.6 billion fell 15.0% year on year, and operating profit of KRW 770 million fell 43.4%. The Q2 rebound did not carry into Q3. Operating profit in Q4 2025 and Q1 2026 was KRW 916 million and KRW 763 million, both at lower levels. Quarterly profit has not built in one consistent direction, which is a weakness.

Falling Operating Margin and Reliance on Financial Factors

The operating margin fell from 5.0% in 2023 to 4.6% in 2024 and 4.3% in 2025. Revenue grew 9.4% in 2025, but operating profit rose only 2.0%. The company explained the 2025 net income gain mainly through lower financial costs tied to exchange rates, not through margin improvement in the core business.

Volatile Operating Cash Flow

Operating cash flow was negative KRW 3.68 billion in 2022 and negative KRW 464 million in 2024. It was positive at KRW 7.37 billion in 2023 and KRW 7.61 billion in 2025, so the swings are large from year to year.

Whether cash generation has kept pace with earnings on a steady basis needs further confirmation in the next annual report.

10

Risk factors

Exchange Rates and Financial Costs

The exchange rate factor that the company cited as the main driver of the 2025 net income gain could reverse direction and move net income. If foreign exchange and translation losses rise again, pre-tax profit comes under pressure. Core operating profit and financial factors need to be read separately.

Shifts in Major Shareholder Stakes

The stake held by Kim Sung-ho and related party Renew Medical changed from 13.99% as of March 16, 2026 to 16.14% as of April 7, 2026. Open-market buying and selling were both disclosed over this period, so the shareholding flow has not been steady. As a small-cap KOSDAQ stock, shifts in holdings can have a relatively large effect on share supply and demand.

Livestock Cycles and Regulatory Change

The feed and animal health business is affected by livestock conditions, herd sizes and feed raw material prices. Changes in disease control policy or feed regulation could alter product demand and registration procedures.

Demand for greenhouse gas reduction products depends on policy direction, so regulatory changes need to be tracked alongside the business.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    Where Q4 2026 operating profit lands between the KRW 1.5 billion of Q2 and the KRW 770 million of Q3 is the first check on the full-year earnings trend.

  2. Early February 2027 (2025 annual results were disclosed on February 6, 2026)

    When 2026 full-year preliminary results come out, they will be compared with the 2025 baseline of KRW 90.8 billion in revenue and KRW 3.92 billion in operating profit. Preliminary figures precede the audited annual report and should be kept separate from disclosed results.

  3. End of March 2027 (within 90 days after fiscal year-end)

    The 2026 annual business report is the next periodic filing. It will contain full-year figures to compare with the 2025 operating margin of 4.3%, the debt ratio of 37.5% and operating cash flow of KRW 7.61 billion.

  4. Mid-May 2027 (within 45 days after quarter-end)

    The Q1 2027 quarterly report will show the direction of quarterly profit against Q1 2026 revenue of KRW 21.5 billion and operating profit of KRW 763 million.

12

Overall view

GeneBioTech's attributable net income has risen for three consecutive years from 2023, and revenue reached KRW 90.8 billion in 2025 after two consecutive years of growth.

However, the operating margin fell from 5.0% in 2023 to 4.3% in 2025, and the company attributes the 2025 net income gain mainly to lower financial costs tied to exchange rates.

Quarterly results are mixed, with operating profit rebounding to KRW 1.5 billion in Q2 2026 before falling to KRW 770 million in Q3, down 43.4% year on year. On the financial side, the debt ratio was 37.5% at the end of 2025 and operating cash flow was positive at KRW 7.61 billion.

Operating cash flow was negative in 2022 and 2024, so the year-to-year swings have been large. Changes in major shareholder stakes continue to be disclosed. The next check points are the 2026 annual business report, which will carry full-year 2026 results, and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. jobkorea.co.kr
  2. comp.fnguide.com
  3. m.jobkorea.co.kr
  4. m.news.nate.com
  5. catch.co.kr
  6. app.rndcircle.io
  7. saramin.co.kr
  8. pignpork.com
  9. sisamagazine.co.kr
  10. digitaltoday.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. genebiotech.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis